Pressure-inactivated yellow fever 17DD virus: Implications for vaccine development

Journal of Virological Methods

Volumn 150, Issue 1-2, 2008, Pages 57-62

  Gaspar, Luciane P ^a   Mendes, Ygara S ^b   Yamamura, Anna M Y ^a   Almeida, Luiz F C ^a   Caride, Elena ^a   Gonçalves, Rafael B ^b   Silva, Jerson L ^b   Oliveira, Andréa C ^b   Galler, Ricardo ^a   Freire, Marcos S ^a  

^a Instituto de Technologia em Imunobiologicos   (Brazil)

^b Centro Nacional de Ressonancia Magnetica Nuclear de Macromoleculas   (Brazil)

Author keywords

High pressure; Virus inactivation; Yellow fever 17DD virus

Indexed keywords

NEUTRALIZING ANTIBODY; YELLOW FEVER VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG SCREENING; HYDROSTATIC PRESSURE; IMMUNOGENICITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VERO CELL; VIRUS CULTURE; VIRUS INACTIVATION; YELLOW FEVER; YELLOW FEVER FLAVIVIRUS;

ANIMALS; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; HYDROSTATIC PRESSURE; MICE; MICROBIAL VIABILITY; NEUTRALIZATION TESTS; PLAQUE ASSAY; SURVIVAL ANALYSIS; VERO CELLS; VIRUS INACTIVATION; YELLOW FEVER; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS;

MURINAE; MUS;

EID: 42649105420     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2008.03.002     Document Type: Article

References (37)

1. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
2. Caufour P.S., Motta M.C., Yamamura A.M., Vasquez S., Ferreira I.I., Jabour A.V., Bonaldo M.C., Freire M.S., and Galler R. Construction, characterization and immunogenicity of recombinant yellow fever 17 D-dengue type 2 viruses. Virus Res. 79 1-2 (2001) 1-14
3. Co M.D., Terajima M., Cruz J., Ennis F.A., and Rothman A.L. Human cytotoxic T lymphocyte responses to live attenuated 17D yellow fever vaccine: identification of HLA-B35-restricted CTL epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural protein E. Virology 293 4 (2002) 511-517
4. Frazatti-Gallina N.M., Mourão-Fuches R.M., Paoli R.L., Silva M.L., Miyaki C., Valentini E.J., Raw I., and Higashi H.G. Vero-cell rabies vaccine produced using serum-free medium. Vaccine 23 4 (2004) 511-517
5. Freire M.S., Mann G.F., Marchevsky R.S., Yamamura A.M., Almeida L.F., Jabor A.V., Malachias J.M., Coutinho E.S., and Galler R. Production of yellow fever 17DD vaccine virus in primary culture of chicken embryo fibroblast: yields, thermo and genetic stability, attenuation and immunogenicity. Vaccine 23 19 (2005) 2501-2512
6. Freitas M.S., Da Poian A.T., Barth M.O., Rebello M.A., Silva J.L., and Gaspar L.P. The fusogenic state of Mayaro virus induced by low pH and by hydrostatic pressure. Cell Biochem. Biophys. 44 3 (2006) 205-211
7. Galler R., Pugachev K.V., Santos C.L., Ocran S.W., Jabor A.V., Rodrigues S.G., Marchevsky R.S., Freire M.S., Almeida L.F., Cruz A.C., Yamamura A.M., Rocco I.M., da Rosa E.S., Sousa L.T., Vasconcelos P.F., Guirakhoo F., and Monath T.P. Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil. Virology 290 2 (2001) 309-319
8. Gaspar L.P., Silva A.C.B., Gomes A.M.O., Freitas M.S., Ano Bom A.P.D., Schwarcz W.D., Mestecky J., Novak M.J., Foguel D., and Silva J.L. Hydrostatic pressure induces the fusion-active state of enveloped viruses. J. Biol. Chem. 277 10 (2002) 8433-8439
9. Gordon J.E., and Hughes T.P. A study of inactivated yellow fever virus as an immunizing agent. J. Immunol. 30 (1936) 221
10. Grove S.F., Lee A., Lewis T., Stewart C.M., Chen H., and Hoover D.G. Inactivation of foodborne viruses of significance by high pressure and other processes. J. Food Prot. 69 4 (2006) 957-968
11. Hindle E. A yellow fever vaccine. Br. Med. J. 1 (1928) 976
12. Ishimaru D., Sá-Carvalho D., and Silva J.L. Pressure-inactivated FMDV: a potential vaccine. Vaccine 22 17-18 (2004) 2334-2339
13. Jurkiewicz E., Villas-Boas M., Silva J.L., Weber G., Hunsmann G., and Clegg R.M. Inactivation of simian immunodeficiency virus by hydrostatic pressure. Proc. Natl. Acad. Sci. U.S.A. 92 15 (1995) 6935-6937
14. Lloyd W., Theiler M., and Ricci N.I. Modification of virulence of yellow fever virus by cultivation in tissues in vitro. R. Soc. Trop. Med. Hyg. 22 (1936) 481-529
15. Liu C.C., Lian W.C., Butler M., and Wu Sc. High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero. Vaccine 25 1 (2007) 19-24
16. Martin M., Tsai T.F., Cropp B., Chang G.J., Holmes D.A., Tseng J., Shieh W., Zaki S.R., Al-Sanouri I., Cutrona A.F., Ray G., Weld L.H., and Cetron M.S. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 358 9276 (2001) 98-104
17. Martins R.M., Galler R., Freire M.S., Camacho L.A.B., Maia M.L.S., and Homma A. Yellow fever vaccination: some thoughts on how much is enough. Vaccine 23 2005 (2007) 3908-3914
18. Mason R.A., Tauraso N.M., Spertzel R.O., and Ginn R.K. Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl. Microbiol. 4 (1973) 539-544
19. Masson P., Tonello C., and Balny C. High pressure biotechnology in medicine and pharmaceutical science. J. Biomed. Biotech. 1 2 (2001) 85-88
20. Merten O.W., Manuguerra J.C., Hannoun C., and Vander Werf S. Production of influenza virus in serum-free mammalian cell cultures. Dev. Biol. Stand. 98 (1999) 23-37
21. Monath T.P., and Nystrom R.R. Detection of yellow fever virus in serum by enzyme immunoassay. Am. J. Trop. Med. Hyg. 33 1 (1984) 151-157
22. Monath T.P., Schlesinger J.J., Brandiss M.W., Cropp C.B., and Prange W.C. Yellow fever monoclonal antibodies: type-specific and cross-reactive determinants identified by immunofluorescence. Am. J. Trop. Med. Hyg. 33 4 (1984) 695-698
23. Murchie L.W., Cruz-Romero M., Kerry J.P., Linton M., Patterson M.F., Smiddy M., and Kelly A.L. High pressure processing of shellfish: a review of microbiological and other quality aspects. Innovative Food Sci. Emerg. Technol. 6 3 (2005) 257-270
24. Paladini A.A., and Weber G. Pressure-induced reversible dissociation of enolase. Biochemistry 20 9 (1981) 2587-2593
25. Pugachev K.V., Guirakhoo F., and Monath T.P. New developments in flavivirus vaccines with special attention to yellow fever. Curr. Opin. Infect. Dis. 18 5 (2005) 387-394
26. Putnak R.J., Coller B.A., Voss G., Vaughn D.W., Clements D., Peters I., Bignami G., Houng H.S., Chen R.C., Barvir D.A., Seriwatana J., Cayphas S., Garcon N., Gheysen D., Kanesa-Thasan N., McDonell M., Humphreys T., Eckels K.H., Prieels J.P., and Innis B.L. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 23 35 (2005) 4442-4452
27. Silva J.L., Luan P., Glaser M., Voss E.W., and Weber G. Effects of hydrostatic pressure on a membrane-enveloped virus: high immunogenicity of the pressure-inactivated virus. J. Virol. 66 4 (1992) 2111-2117
28. Silva J.L., Foguel D., Da Poian A.T., and Prevelige P.E. The use of hydrostatic pressure as a tool to study viruses and other macromolecular assemblages. Curr. Opin. Struct. Biol. 6 2 (1996) 166-175
29. Stefano I., Sato H.K., Pannuti C.S., Omoto T.M., Mann G., Freire M.S., Yamamura A.M., Vasconcelos P.F., Oselka G.W., Weckx L.W., Salgado M.F., Noale L.F., and Souza V.A. Recent immunization against measles does not interfere with the sero-response to yellow fever vaccine. Vaccine 17 9-10 (1999) 1042-1046
30. Struchiner C.J., Luz P.M., Dourado I., Sato H.K., Aguiar S.G., Ribeiro J.G.L., Soares R.C.R., and Codeço C.T. Risk of fatal adverse events associated with 17DD yellow fever vaccine. Epidemiol. Infect. 132 5 (2004) 939-946
31. Theiller M., and Smith H.H. The effect of prolonged cultivation in vitro upon the pathogenicity of yellow fever virus. J. Exp. Med. 65 (1937) 767-786
32. Theiller M., and Smith H.H. Use of yellow fever virus modified by in vitro cultivation for human immunization. J. Exp. Med. 65 (1937) 787-800
33. Tian S.M., Qian J.F., Shao G.Q., and Ruan K.C. High immunogenicity of the pressure-inactivated virus. Acta Bioch. Biophys. Sin. 31 3 (1999) 334-336
34. Tian S.M., Ruan K.C., Qian J.F., Shao G.Q., and Balny C. Effects of hydrostatic pressure on the structure and biological activity of infectious bursal disease virus. Eur. J. Biochem. 267 14 (2000) 4486-4494
35. van der Most R.G., Harrington L.E., Giuggio V., Mahar P.L., and Ahmed R. Yellow fever virus 17D envelope and NS3 proteins are major targets of the antiviral T cell response in mice. Virology 296 1 (2002) 117-124
36. Vasconcelos P.F., Luna E.J., Galler R., Silva L.J., Coimbra T.L., Barros V.L., Monath T.P., Rodrigues S.G., Laval C., Costa Z.G., Vilela M.F., Santos C.L., Papaiordanou P.M., Alves V.A., Andrade L.D., Sato H.K., Rosa E.S., Froguas G.B., Lacava E., Almeida L.M., Cruz A.C., Rocco I.M., Santos R.T., and Oliva O.F. Brazilian Yellow Fever Vaccine Evaluation Group. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 358 9276 (2001) 91-97
37. Wu S.C., Liu C.C., and Lian W.C. Optimization of microcarrier cell culture process for the inactivated enterovirus type 71 vaccine development. Vaccine 22 29-30 (2004) 3858-3864